AQP4 and Autoimmunity: Despite the promising results, a number of patients had persisting AQP4 antibodies and relapsed within 5, and the optimal conditioning regimen remains to be determined as well [110] Based on these findings, the European Bone Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) issued guidelines recommending the use of AHSCT in NMOSD as a clinical option, with grade II evidence, in therapy-refractory patients [104].